血液肿瘤患者AHSCT后DC/CIK免疫治疗的疗效观察

目的应用树突状细胞(dendritic cell,DC)/细胞因子诱导的杀伤细胞(cytokine induced killer cell,CIK)细胞免疫治疗自体造血干细胞移植后完全缓解血液肿瘤患者,观察疗效。方法采集12例血液肿瘤自体造血干细胞移植后完全缓解患者的外周血单个核细胞,在体外经GM-CSF、IL-4、TNF-α等诱导产生DC,经IFN-γ、抗CD3单抗、IL-2等诱导产生CIK,观察其临床应用的不良反应及疗效。结果在DC/CIK细胞免疫治疗过程中,3例患者DC注射部位出现轻微疼痛,可自行缓解。2例患者输注完CIK后出现低热,持续时间2～6 h,可自行消退;4例患者输注完CIK后出现乏力,约2 h可自行缓解。7例仍完全缓解(CR),中位CR期18(5～32)个月,2例为非常好的部分缓解(VGPR)或疾病稳定(SD),3例复发或疾病进展(PD),其中1例复发死亡。结论 DC/CIK细胞免疫治疗自体造血干细胞移植(AutologousHematopoietic Stem Cell Transplantation,AHSCT)后完全缓解的血液肿瘤患者,安全性好,不良反应少,有较好的临床应用前景。

Curative Effect of DC/CIK Cellular Immunotherapy after Autologous Hematopoietic Stem Cell Transplantation in Patients with Hematologic Malignancies

Objective To observe the curative effects of dendritic cells(DC)/cytokine induced killer cell(CIK) cellular immunotherpy after autologous hematopoietic stem cell transplantation in patients with hematologic malignancies.Methods Peripheral blood mononuclear cells(PBMC) from 12 complete remission patients with hematologic malignancies of treated by autologous stem cell transplantation were collected and induced in vitro by GM-CSF,IL-4,TNF-α for DC,and by INF-γ,Anti-CD3,IL-2 for CIK.The adverse reactions and curative effects were recorded.Results In the DC/CIK cellular immunotherapy,3 cases were with a slight pain in the subcutaneous DC injection site and were relieved spontaneously;2 cases with low fever lasted 2-6 hours after CIK and relieved spontaneously;7 cases were complete remission(CR).4 cases with fatigue after CIK injection and relieved 2 hours later;the median period of CR was 18(range 5 to 32) months,2 cases were with very good partial remission(VGPR) or stable disease(SD),3 cases with recurrence or progression disease(PD) in which one died.Conclusion DC/CIK cellular immunotherapy after the autologus hematopoietic stem cell transplantation in complete remission patients of the hematologic malignancies is with a good safety,less adverse reaction and good perspective in clinical appliance.